Previous close | 10.00 |
Open | 10.09 |
Bid | 7.36 x 200 |
Ask | 12.67 x 200 |
Day's range | 9.82 - 10.23 |
52-week range | 2.74 - 12.00 |
Volume | |
Avg. volume | 2,116,072 |
Market cap | 2.246B |
Beta (5Y monthly) | 1.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update. Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m. ET on Monday, May 13, 2024.Sana will present at the BofA Securities 2024 Healthcar
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announced SC262 IND
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of